Sunshine Silver Mining & Refining saw its shares rise 27% during its debut on the New York Stock Exchange, signaling strong investor interest. AstraZeneca celebrated its transfer to the NYSE, noted as the largest by market capitalization in the exchange's 234-year history. Meanwhile, fintech company RedotPay introduced a new B2B product aimed at cutting global merchant fees by 70%. These developments highlight active market movements and innovation ahead of trading sessions.
AstraZeneca CEO Pascal Soriot highlighted that artificial intelligence (AI) is significantly enhancing the company's ability to develop medicines faster and make smarter research decisions. AI tools help identify promising drug targets, optimize mole...
PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle during GLP-1 therapy. The report highlights growing industry interest, strategic acquisitions by ...
PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle mass alongside GLP-1 therapies. This emerging category is gaining industry attention due to its p...
Deutsche Bank maintains a sell rating on AstraZeneca with a price target of 11,500p, despite shares trading at 13,064p. The bank views the recent ASCO conference data, including the positive phase III EMERALD-3 trial for liver cancer, as incremental ...
Deutsche Bank maintained its sell rating and 11,500p price target on AstraZeneca shares despite positive phase III trial results presented at the ASCO 2026 conference. The EMERALD-3 trial showed a 30% reduction in disease progression risk for a liver...
